AUT00201 is a potent, selective Kv3 potassium channel modulator with potential for the treatment of rare epilepsy syndromes.

ACOU085 (ACOU 085) is a potent small-molecule agonist of Kv7.4 (KCNQ4) channel with higher potency than ML-213 in the nanomolar range.

ACOU001 (ACOU 001) is a potent small-molecule agonist of Kv7.4 (KCNQ4) channel with potential effect against ge-related hearing loss (ARHL) and other hearing impairments related to compromised KV7.4 function.

Filapixant (BAY1902607) is a potent, selective P2X3 receptor antagonist, shows a substantially higher in vitro selectivity for P2X3 over P2X2 when compared with Eliapixant (BAY1817080, Cat# PC-72754).

DT-0111 (DT0111) is a selective and effective, water-soluble antagonist at P2X2/3R, does not activate or block P2YR, inhibits ATP-induced current in nodose ganglionic cells with IC50 of 0.3 uM.

RGH-560 (RGH560) is a potent, selective α7 nAChR positive allosteric modulator (PAM) with EC50 of 190 nM (Ca2+-influx).

MK4334 is a potent, selective positive allosteric modulator (PAM) of the α7 nAChR with potential for treatment of Alzheimer's disease.

JWX-A0108 is a novel selective type I α7 nAChR positive allosteric modulator (PAM) with EC50 of 4.35 uM, shows no potentiation effect on α3β4 nAChR, α4β2 nAChR, or 5-HT3AR.

DM506 is a novel ibogamine derivative and inhibitor of α7 and α9α10 nicotinic acetylcholine receptors (nAChRs) with IC50 of 5.1 uM, 5.6 uM and 6.4 uM for α9α10, α7β2 and α7nAChR, respectively.

CVN417 (CVN-417) is a potent, selective and brain-penetrant α6-containing nicotinic acetylcholine receptor (α6 nAChR) antagonist with Ca2+ flux IC50 of 86 nM.

Cris-104 is a selective α4β2* neuronal nAChR agonist, demonstrates antinociceptive and antihypersensitivity in rodent acute/inflammatory and chronic pain models.

AT1001 (AT-1001) is a high affinity and selective α3β4 nAChR antagonist with Ki value of 2.4 nM, >90-fold selectivity over the other major subtypes (α4β2 and α7 nAChR).

AN317 is a functionally selective, partial agonist of α6β2-containing nicotinic acetylcholine receptor (nAChR) with pEC50 of 7.17 (α6/α3β2β3V9'S receptor) in cell-based assays, inhibits the effect of nicotine with IC50 of 1.1 uM.

Tebanicline dihydrochloride (ABT-594) is a potent, orally active neuronal nicotinic acetylcholine receptor (alpha 4 beta 2 nAChR) agonist with Ki of 37 pM (rat brain) and 55 pM (transfected human receptor).

ABT-418 hydrochloride (ABT418) is an analog of (-)-nicotine and cholinergic ligand (activator) of nAChRs, a potent inhibitor of [3H]-cytisine binding to nAChR in rat brain with Ki of 2 nM.

ZINC000443438219 (Compound 8219) is a highly potent, selective and non-competitive inhibitor of serotonin transporter (SERT) with Ki of 3 nM.

ZINC000006658090 (Compound 8090) is a highly potent, selective and non-competitive inhibitor of serotonin transporter (SERT) with Ki of 14 nM.

SRI-32743 is a novel allosteric modulator of dopamine transporter (DAT), attenuates HIV-1 Tat protein-induced inhibition of the dopamine transporter.

Lu AF60097 is a high affinity, allosteric inhibitor of serotonin transporter (SERT) inhibitor with IC50 of 31 nM for inhibition of [3H]IMI dissociation, targets the extracellular vestibule (S2 site).

LQFM215 (LQFM-215) is a synthetic L-proline transporter (PROT/SLC6A7) inhibitor, inhibits proline uptake in hippocampal synaptosome with IC50 of 20.4 uM, present neuroprotective potential.

JJC8-091 is a potent, Modafinil-derived dopamine transporter (DAT) ligand with Ki of 16.7 nM, attenuates compulsive-like methamphetamine self-administration in rats.

JJC8-088 is a potent, Modafinil-derived dopamine transporter (DAT) ligand with Ki of 2.53 nM.

JJC8-016 is a potent, Modafinil-derived dopamine transporter (DAT) ligand with Ki of 116 nM, attenuates compulsive-like methamphetamine self-administration in rats.

GZ-794A is a potent, selective inhibitor of vesicular monoamine transporter-2 (VMAT2) with Ki of 30 nM, inhibits methamphetamine-evoked endogenous dopamine release with IC50 of 0.4 uM, shows potential for treatment for methamphetamine abuse.

GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with Ki of 25 nM, GZ-11608 (EC50=620 nM) released vesicular dopamine 25-fold less potently than it inhibited VMAT2 dopamine uptake.

FFN200 is a vesicular monoamine transporter 2 (VMAT2) substrate, and the first probe to selectively trace monoamine exocytosis in both neuronal cell culture and brain tissue.

D-578 is a potent, orally active triple monoamine reuptake inhibitor with Ki values of 16.2. 16.2, 3.23 nM, and 29.6, 20.6, 6.10 nM for the rat brain and cloned human dopamine, serotonin and norepinephrine transporters, respectively.

CDTP-32476 is a potent slow-onset dopamine reuptake blocker with an affinity of 8.6 nM, CDTP-32476 is moderately selective (14-fold) versus NE reuptake blockade with little effect on the SERT.

(S)-CE-123 is a specific small molecule dopamine transporter (DAT) inhibitor, improves memory acquisition and memory retrieval.

ZCAN262 is a small molecule that prevents AMPA-mediated excitotoxicity (IC50=8.5 nM) by targeting an allosteric binding site of AMPA glutamate receptor 2 (GluA2).